AusCann Group’s (ASX: AC8) hard shell medicinal cannabis products are now available for prescription Australia-wide, with clinical trials also ready to kick-off into evaluating different doses of its THC-CBD formulations.
In parallel with the upcoming clinical study, AusCann has made its medicinal cannabis capsules available to Australian patients via the Therapeutic Goods Administration Special Access Scheme.
As part of this, AusCann has shipped the hard-shell capsules to its distribution partner CH2, with authorisation now granted for prescription sales across the country.
“AusCann has developed standardised cannabinoid-based formulations in a dose-controlled capsule,” AusCann chief executive officer Ido Kanyon said.
“The capsules have been tested in a lab setting and demonstrated to be reliable, stable and deliver a consistent controlled dose of the formulations.”
He added the company was now excited to begin clinical evaluation of the capsules to demonstrate their benefits.
Making the hard-shell capsules commercially available now is ahead of the company’s previously outlined deadline of targeting distribution before mid-year.